12-lipoxygenase inhibitor VLX-1005
A selective small molecule inhibitor of 12-lipoxygenase (12-LOX), with potential anti-platelet and anti-thrombotic activities. Upon intravenous administration, 12-LOX inhibitor VLX-1005 inhibits platelet 12-LOX. This modulates Fc gamma receptor IIa (FcgRIIa; CD32a) signaling, inhibits FcgRIIa-mediated platelet activation and aggregation, and reduces thrombus formation. The activation of the FcgRIIa receptor plays an important role in immune-mediated thrombosis, such as heparin-induced thrombocytopenia (HIT). 12-LOX, an enzyme expressed in platelets, regulates FcgRIIa activity in the platelet.
| Synonym: | 12-LOX inhibitor VLX-1005 |
|---|---|
| Code name: | ML 355 ML-355 ML355 VLX 1005 VLX-1005 VLX1005 |
| Chemical structure: | benzenesulfonamide, N-2-benzothiazolyl-4-(((2-hydroxy-3-methyoxyphenyl)methyl)amino)- N-2-benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)benzenesulfonamide |